Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.

The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.

Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.

Novartis hopes to prevent, treat and block malaria and is conducting clinical trials to test some promising therapies. Learn more.

Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

The best treatment for multifaceted diseases like NASH may be combinations of drugs.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).